Stockwatch: Orphans are better, if they work
This article was originally published in Scrip
Executive Summary
InterMune’s therapeutic area for many years has been lung diseases and more specifically idiopathic pulmonary fibrosis (IPF). The company's treatment for IPF, pirfenidone, is the only approved drug, and yet it is not available everywhere. The US FDA, for instance, issued a complete response letter in May. Furthermore, InterMune's original intention of partnering its drug has not been realised. What lies behind such regulatory and commercial reticence?
You may also be interested in...
Stockwatch: Pandemic And Biosimilar Effects Subordinate Early Third-Quarter Earnings Results
Early in 2020, company guidance was that pandemic-related effects would have dissipated in the third quarter. Issues specific to J&J and Roche leave this broad conclusion still up in the air.
Stockwatch: Some Failed Drugs Never Die, They Just Find New Investors
Drugs that have failed in clinical studies often come back for another go, making the same mistakes for a new cohort of investors who missed the first failure. The global pandemic is also enabling this for once- or twice-failed drugs.
Stockwatch: Batsu Games − Drug And Vaccine Development
Batsu is the Japanese term for games that have penalties, unlike those which are just for fun. Seasoned investors are well aware of the risks of drug and vaccine development but many investors new to the sector are just learning of the downsides.
Need a specific report? 1000+ reports available
Buy Reports